Grant: Operating Grant
Université Laval
$100,000.00
Glycogen synthase kinase 3 signaling cascades mediating psychiatric drug action
EF 2015-16
Résumé
Most, pharmacological principles used in psychiatry have been discovered by serendipity in the 1950s and 60s. Identification of the primary targets of these first generation drugs has led to an explosion of psychopharmacology blockbusters in the late 20th century. However, psychiatric drug development has since stalled mostly due to a lack of significant new drug target. Mood stabilizers like lithium are drugs used to manage bipolar disorder, an important mental illness affecting 2% of the population. Mood stabilizers exert some of their therapeutic action by inhibiting the serine threonine kinase Glycogen synthase kinase 3 beta (GSK3). Pharmacological inhibition of GSK3 has thus become an important new strategy for the treatment of mental illnesses. However, several limitations associated to the specificity and long-term toxicity of GSK3 inhibitors remains serious obstacles. We have identified FXR1P, an RNA binding protein of the fragile X family, as a new substrate of GSK3 implicated in the behavioral actions of psychiatric drugs. We propose to examine the regulation of FXR1P by GSK3 and its implications in the action of mood stabilizers. This project will involve 1- the characterization of the mechanisms by which GSK3 regulates FXR1P. 2- The characterization of the role played by FXR1P in the effects of psychiatric drugs and 3- the elucidation of the mechanisms by which FXR1P contributes to the regulation of behavior. Research conducted within this project will allow tackling the contribution of FXR1P to the action of mood stabilizers. This will result in a better understanding of the action of existing psychoactive compounds and provide new avenues for the development of more effective approaches for the treatment of bipolar disorders.
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
333450
Name
Beaulieu Martin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Pharmacology & Toxicology
Projecttitle
Glycogen synthase kinase 3 signaling cascades mediating psychiatric drug action
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Antidepressant; Antipsychotics; Cell Signaling; Drug Target; Gsk3; Mood And Emotions; Mood Stabilizers; Protein Translation; Psychoactive Drugs; Rna Binding Protein
Abstract
Most, pharmacological principles used in psychiatry have been discovered by serendipity in the 1950s and 60s. Identification of the primary targets of these first generation drugs has led to an explosion of psychopharmacology blockbusters in the late 20th century. However, psychiatric drug development has since stalled mostly due to a lack of significant new drug target. Mood stabilizers like lithium are drugs used to manage bipolar disorder, an important mental illness affecting 2% of the population. Mood stabilizers exert some of their therapeutic action by inhibiting the serine threonine kinase Glycogen synthase kinase 3 beta (GSK3). Pharmacological inhibition of GSK3 has thus become an important new strategy for the treatment of mental illnesses. However, several limitations associated to the specificity and long-term toxicity of GSK3 inhibitors remains serious obstacles. We have identified FXR1P, an RNA binding protein of the fragile X family, as a new substrate of GSK3 implicated in the behavioral actions of psychiatric drugs. We propose to examine the regulation of FXR1P by GSK3 and its implications in the action of mood stabilizers. This project will involve 1- the characterization of the mechanisms by which GSK3 regulates FXR1P. 2- The characterization of the role played by FXR1P in the effects of psychiatric drugs and 3- the elucidation of the mechanisms by which FXR1P contributes to the regulation of behavior. Research conducted within this project will allow tackling the contribution of FXR1P to the action of mood stabilizers. This will result in a better understanding of the action of existing psychoactive compounds and provide new avenues for the development of more effective approaches for the treatment of bipolar disorders.
Competitiondate
201505
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beaulieu, Martin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~